Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. It provides products and services for basic research and industrial application in life sciences. These include services for the research and manufacturing of regenerative medicine products and the development of gene therapy products for synovial sarcoma. It also develops, manufactures, and sells reagents for polymerase chain reaction (PCR) tests for COVID-19. The company was founded on April 1, 2002 and is headquartered in Kusatsu, Japan.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
1,793
Frequently Asked Questions
What is Takara Bio Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Takara Bio Inc.'s EBITDA is 17.52.